Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (18)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Amin, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Amin, N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2002) 17: 340-345
© 2002 European Renal Association-European Dialysis and Transplant Association


The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure

Naseem Amin

Genzyme Corporation, Cambridge, MA, USA

Abstract

Phosphorus control is a primary goal in the care of patients with end-stage renal disease (ESRD). Sevelamer hydrochloride, a novel calcium-free, aluminum-free phosphate binder, allows physicians to control serum phosphorus in patients with ESRD without increasing serum calcium levels or contributing an excess calcium load. Clinical studies have shown that sevelamer provides sustained reduction in markers of soft-tissue and cardiac calcification, specifically serum phosphorus, calciumxphosphorus product, parathyroid hormone and also improves blood lipid profiles. Thus, sevelamer hydrochloride offers the promise of impacting cardiac calcification and thereby reducing patient morbidity and mortality. Long-term studies are underway to evaluate these potential benefits. This paper reviews sevelamer studies to date and addresses ongoing strategies for improving clinical management of phosphorus in ESRD.

Keywords: calcium; chronic renal failure; hyperphosphataemia; phosphate binder; phosphorus; sevelamer hydrochloride

Notes

Correspondence and offprint requests to: Naseem Amin, MD, Genzyme Corporation, One Kendall Square, Cambridge, MA 02139, USA. Email: Naseem.Amin{at}genzyme.com


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
N. Nagano, S. Miyata, M. Abe, S. Wakita, N. Kobayashi, and M. Wada
Sevelamer hydrochloride reverses parathyroid gland enlargement via regression of cell hypertrophy but not apoptosis in rats with chronic renal insufficiency
Nephrol. Dial. Transplant., March 1, 2006; 21(3): 634 - 643.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
B. Cizman
Hyperphosphataemia and treatment with sevelamer in haemodialysis patients
Nephrol. Dial. Transplant., July 1, 2003; 18(90005): v47 - 49.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
N. Nagano, S. Miyata, S. Obana, N. Kobayashi, M. Abe, N. Fukushima, and M. Wada
Sevelamer hydrochloride, a calcium-free phosphate binder, inhibits parathyroid cell proliferation in partially nephrectomized rats
Nephrol. Dial. Transplant., March 1, 2003; 18(90003): iii81 - 85.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.